M
Misty M. Attwood
Researcher at Uppsala University
Publications - 26
Citations - 2281
Misty M. Attwood is an academic researcher from Uppsala University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 8, co-authored 17 publications receiving 1158 citations. Previous affiliations of Misty M. Attwood include I.M. Sechenov First Moscow State Medical University.
Papers
More filters
Journal ArticleDOI
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser,Misty M. Attwood,Mathias Rask-Andersen,Helgi B. Schiöth,David E. Gloriam +4 more
TL;DR: An up-to-date analysis of all GPCR drugs and agents in clinical trials is reported, which reveals current trends across molecule types, drug targets and therapeutic indications, including showing that 475 drugs act at 108 unique GPCRs.
Journal ArticleDOI
Trends in kinase drug discovery: targets, indications and inhibitor design.
Misty M. Attwood,Doriano Fabbro,Aleksandr V. Sokolov,Stefan Knapp,Stefan Knapp,Helgi B. Schiöth,Helgi B. Schiöth +6 more
TL;DR: In this paper, the authors analyzed the landscape of approved and investigational therapies that target kinases and trends within it, including the most popular targets of kinase inhibitors and their expanding range of indications.
Journal ArticleDOI
Recent developments of HDAC inhibitors: Emerging indications and novel molecules.
Andrey D. Bondarev,Andrey D. Bondarev,Misty M. Attwood,Jörgen Jonsson,Vladimir N. Chubarev,Vadim V. Tarasov,Helgi B. Schiöth,Helgi B. Schiöth +7 more
TL;DR: The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets as mentioned in this paper and have been identified as a promising therapeutic target.
Journal ArticleDOI
Soluble ligands as drug targets.
TL;DR: This Review analyses drugs targeting ligands that have reached clinical development in the past three decades and discusses strategic issues such as the pros and cons of different ligand-targeting therapeutic modalities.
Journal ArticleDOI
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
Amelia Dahlén,Giovanna Dashi,Ivan Maslov,Misty M. Attwood,Jörgen Jonsson,V. M. Trukhan,Helgi B. Schiöth +6 more
TL;DR: Modern drugs, such as glucagon-like peptide-1 (GLP-1) receptor agonists, DPP4 inhibitors and SGLT2 inhibitors have gained popularity on the pharmaceutical market, while less expensive over the counter alternatives are increasing in developing economies.